Pramipexole in peritoneal dialysis patients with restless legs syndrome (RLS): a protocol for a multicentre double-blind randomised controlled trial

Tian-Tian Ma, Zhikai Yang, Sainan Zhu, Jing-Hong Zhao, Yi Li, Fu-Yun Sun, Nan Zhao, Zu-Ying Xiong, Zi-Bo Xiong, Jie Dong, Tian-Tian Ma, Zhikai Yang, Sainan Zhu, Jing-Hong Zhao, Yi Li, Fu-Yun Sun, Nan Zhao, Zu-Ying Xiong, Zi-Bo Xiong, Jie Dong

Abstract

Introduction: Restless legs syndrome (RLS) is a common neurological sensorimotor disorder among patients with end stage renal disease. This clinical trial aimed to provide evidence on the efficacy and safety of pramipexole in patients with uremic RLS receiving peritoneal dialysis (PD).

Methods and analysis: This is a 12-week, multicentre, randomised, double-blind, placebo-controlled clinical trial. In total, 104 patients with uremic RLS receiving PD will be enrolled from four hospitals and randomly assigned in a 1:1 ratio to either placebo or pramipexole. We will determine the efficacy of pramipexole in the improvement of International RLS Study Group Rating Scale as the primary outcome, while responder rates for other RLS scales at week 12, change from baseline to week 12 for psychological status, sleep disorder and quality of life and blood pressure represent the secondary outcomes.

Ethics and dissemination: The study was approved by the ethics committees of Peking University First Hospital, Xinqiao hospital of Army Medical University, Cangzhou Center Hospital and Peking University Shenzhen Hospital. The results will be disseminated in peer-reviewed journals.

Trial registration number: NCT03817554.

Keywords: dialysis; neurology; protocols & guidelines.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of the participants in the study. IRLS, International RLS Study Group Rating Scale; RLS, restless legs syndrome.

References

    1. Allen RP, Picchietti D, Hening WA, et al. . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of health. Sleep Med 2003;4:101–19. 10.1016/s1389-9457(03)00010-8
    1. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, et al. . Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int 2014;85:1275–82. 10.1038/ki.2013.394
    1. Unruh ML, Levey AS, D'Ambrosio C, et al. . Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004;43:900–9. 10.1053/j.ajkd.2004.01.013
    1. Losso RLM, Minhoto GR, Riella MC. Sleep disorders in patients with end-stage renal disease undergoing dialysis: comparison between hemodialysis, continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. Int Urol Nephrol 2015;47:369–75. 10.1007/s11255-014-0860-5
    1. Tekdöş Demircioğlu D, Kavadar G, Esen Öre Özgül, et al. . Relationship between restless leg syndrome and quality of life in uremic patients. Agri 2015;27:73–8. 10.5505/agri.2015.19327
    1. La Manna G, Pizza F, Persici E, et al. . Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 2011;26:1976–83. 10.1093/ndt/gfq681
    1. Zucconi M, Manconi M, Ferini Strambi L. Aetiopathogenesis of restless legs syndrome. Neurol Sci 2007;28:S47–52. 10.1007/s10072-007-0737-9
    1. Allen RP. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007;120:S13–21. 10.1016/j.amjmed.2006.11.003
    1. Takaki J, Nishi T, Nangaku M, et al. . Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis 2003;41:833–9. 10.1016/S0272-6386(03)00031-3
    1. Collado-Seidel V, Kohnen R, Samtleben W, et al. . Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998;31:324–8. 10.1053/ajkd.1998.v31.pm9469505
    1. Marconi S, Scaglione C, Pizza F, et al. . Group I nonreciprocal inhibition in restless legs syndrome secondary to chronic renal failure. Parkinsonism Relat Disord 2012;18:362–6. 10.1016/j.parkreldis.2011.12.002
    1. Silber MH, Becker PM, Earley C, et al. . Willis-Ekbom disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 2013;88:977–86. 10.1016/j.mayocp.2013.06.016
    1. de Biase S, Pellitteri G, Gigli GL, et al. . Advancing synthetic therapies for the treatment of restless legs syndrome. Expert Opin Pharmacother 2019;20:1971–80. 10.1080/14656566.2019.1654997
    1. de Biase S, Merlino G, Valente M, et al. . Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 2016;12:1035–45. 10.1080/17425255.2016.1198320
    1. Antonini A, Calandrella D. Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol 2011;7:1307–14. 10.1517/17425255.2011.614232
    1. Liu GJ, Wu L, Lin Wang S, et al. . Efficacy of pramipexole for the treatment of primary restless leg syndrome: a systematic review and meta-analysis of randomized clinical trials. Clin Ther 2016;38:162–79. 10.1016/j.clinthera.2015.10.010
    1. Montagna P, Hornyak M, Ulfberg J, et al. . Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12:34–40. 10.1016/j.sleep.2010.08.005
    1. Miranda M, Kagi M, Fabres L, et al. . Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004;62:831–2. 10.1212/01.WNL.0000113752.14744.15
    1. Pellecchia MT, Vitale C, Sabatini M, et al. . Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 2004;27:178–81. 10.1097/01.wnf.0000135480.78529.06
    1. Gopaluni S, Sherif M, Ahmadouk NA. Interventions for chronic kidney disease-associated restless legs syndrome. Cochrane Database Syst Rev 2016;11:Cd010690 10.1002/14651858.CD010690.pub2
    1. Wright CE, Sisson TL, Ichhpurani AK, et al. . Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520–5. 10.1002/j.1552-4604.1997.tb04330.x
    1. Montplaisir J, Nicolas A, Denesle R, et al. . Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938–43. 10.1212/WNL.52.5.938

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit